10-Q: Modular Medical Faces Going Concern, Nasdaq Delisting Risk

Modular Medical, Inc. reported increased operating losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, while also facing Nasdaq delisting due to its stock price.

Summary

• Net loss increased to $6.7 million for the three months ended June 30, 2025, from $4.1 million in the prior year period.
• Cash and cash equivalents decreased to $7.5 million as of June 30, 2025, from $13.1 million at March 31, 2025.
• Operating expenses rose significantly, with Research and Development (R&D) up 60.1% to $5.1 million and Selling, General and Administrative (SG&A) up 64.6% to $1.7 million.
• The company received FDA clearance for its MODD1 insulin pump in September 2024 and expects initial shipments by October 2025.
• Modular Medical is developing an updated tubeless version, the Pivot, and intends to replace MODD1 upon regulatory approval, expected in the first half of 2026.
• The company received a Nasdaq non-compliance letter for failing to maintain a minimum bid price of $1 per share, with a deadline of December 29, 2025, to regain compliance.
• Management expressed substantial doubt about the company's ability to continue as a going concern for at least one year without additional capital.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including a significant net loss, substantial cash burn, and a going concern warning. The Nasdaq delisting notice adds considerable risk. While product development continues with FDA clearance for MODD1 and plans for Pivot, these positives are heavily outweighed by the immediate financial and operational uncertainties.

Positives

• Received FDA clearance to market and sell the MODD1 insulin pump in the United States in September 2024.
• Expects initial shipments of the MODD1 product by October 2025.
• Actively developing an updated, tubeless version of the product, the Pivot, which is expected to offer cost and usability improvements and improved manufacturability.
• Increased R&D investment by 60.1% to $5.1 million, indicating continued product development efforts.

Negatives

• Net loss increased to $6.7 million for the three months ended June 30, 2025, compared to $4.1 million for the same period in 2024.
• Cash and cash equivalents significantly decreased to $7.5 million at June 30, 2025, from $13.1 million at March 31, 2025.
• Accumulated deficit grew to $91.5 million as of June 30, 2025.
• Operating expenses increased substantially, with R&D up 60.1% and SG&A up 64.6%.
• The company is pre-revenue and does not generate cash flows to cover operating expenses, leading to a substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq non-compliance letter for failing to maintain a minimum bid price of $1 per share, risking delisting.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least one year due to recurring operating losses and negative cash flows.
• There is no assurance that additional capital, whether debt or equity, will be sufficient or available on acceptable terms, potentially leading to curtailment of R&D or termination of operations.
• If additional securities are issued to raise funds, existing stockholders may experience dilution, and new securities may have senior rights.
• Failure to regain compliance with Nasdaq's $1 minimum bid price requirement by December 29, 2025, could lead to delisting, adversely affecting stock liquidity, ability to raise capital, and investor confidence.
• The company is subject to risks inherent in its industry, including competition, financing, liquidity requirements, rapidly changing customer requirements, and market volatility due to its limited operating history.
• Potential for increasing costs for components and related issues due to inflationary risks.
• The company's future success depends on its ability to successfully commercialize its pump products.
• Risk from competing technological and market developments.

Future Outlook

The company expects initial shipments of its MODD1 insulin pump by October 2025. It is preparing a 510(k) premarket notification for an updated tubeless product, the Pivot, with an expected submission by October 31, 2025, and regulatory clearance in the first half of 2026. The Pivot product is intended to replace MODD1, offering cost, usability, and manufacturability improvements. Research and development expenses are expected to remain consistent in fiscal 2026, while selling, general and administrative expenses are projected to increase to support commercialization.

Management Comments

• "We are actively working to commercialize our MODD1 product and commence initial shipments by October 2025, obtain regulatory clearance to market and sell our Pivot product during the first half of 2026, obtain regulatory clearance to market and sell our pump products in foreign jurisdictions, improve the manufacturability and usability of our pump products and develop new pump products."
• "We believe the Pivot product will provide us with cost and usability improvements and improved manufacturability, allowing our marketing to be focused on low cost and ease of use and learnability."
• "We intend to replace the MODD1 product with the Pivot product, as soon as the required regulatory approval from the FDA is received."
• "Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued exists."
• "Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations."
• "If we are unable to secure additional capital timely, we may be required to curtail R&D initiatives, reduce headcount and take additional measures to reduce costs in order to conserve our cash."
• "We are monitoring the closing bid price of our common stock and considering our available options in the event the closing bid price of our common stock remains below $1 per share."

Industry Context

Modular Medical operates in the highly competitive and rapidly evolving medical device industry, specifically targeting the diabetes market with innovative insulin pumps. The company aims to expand the wearable insulin delivery device market beyond highly motivated 'super users' to a broader mass market, including Type 1 and the growing Type 2 diabetes segments, by simplifying user experience and focusing on cost-effectiveness. Its strategy to introduce an updated 'Pivot' product shortly after the initial MODD1 launch suggests a focus on continuous innovation and addressing market feedback quickly, which is common in fast-paced tech-driven medical fields. However, the pre-revenue status and significant cash burn highlight the substantial capital requirements and long development cycles typical for medical device companies prior to commercial success.

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• Paid approximately $52,700 to a family member of an executive officer who is an employee during the three months ended June 30, 2025.
• Paid approximately $18,600 to a second family member of an executive officer who consulted with and became an employee during the three months ended June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises, risk of substantial loss of investment due to going concern issues, and potential loss of liquidity and institutional interest if delisted from Nasdaq.
• Employees: Continued investment in R&D and increased headcount in R&D (to 55) and SG&A (to 12) indicate growth in personnel, but potential for headcount reductions if additional capital is not secured.
• Customers: Expected initial shipments of MODD1 by October 2025 and future Pivot product offer new options for diabetes management, but long-term product availability depends on the company's financial viability.
• Creditors: Increased total liabilities and significant operating losses raise concerns about the company's ability to meet future obligations.
• Suppliers: Outstanding purchase orders for machinery and equipment ($2.4 million) and technology commitments ($0.9 million) indicate ongoing business, but financial instability could impact future orders and payments.

Next Steps

• Commence initial shipments of the MODD1 product by October 2025.
• Submit a 510(k) premarket notification application to the FDA for the Pivot pump product on or before October 31, 2025.
• Regain compliance with Nasdaq's $1 minimum bid price requirement by December 29, 2025.
• Validate the manufacturing line for the Pivot pump product with capacity to serve 6,000 patients by March 15, 2026.
• Obtain regulatory clearance to market and sell the Pivot product during the first half of 2026.
• Obtain regulatory clearance to market and sell pump products in foreign jurisdictions.
• Improve the manufacturability and usability of pump products.
• Develop new pump products.
• Seek additional financing through equity or debt securities to support future operations.
• Evaluate the impact of ASU No. 2024-03 on financial statement presentation.

Key Dates

Recommendation

Modular Medical, Inc. is in a precarious financial position, evidenced by a substantial net loss of $6.7 million, a significant cash burn reducing cash to $7.5 million, and an explicit 'going concern' warning from management and auditors. The company is pre-revenue, relying entirely on capital raises to fund operations. Furthermore, the Nasdaq non-compliance notice for its minimum bid price, with a looming December 29, 2025 deadline, presents a material risk of delisting, which would severely impact liquidity and investor confidence. While FDA clearance for MODD1 and plans for the Pivot pump are positive product developments, the company's severe liquidity issues and the high probability of further dilution or operational curtailment make it a high-risk investment. A seasoned investor would likely view the current financial state and regulatory challenges as overwhelmingly negative, warranting a strong sell recommendation to mitigate further potential losses.

Keywords

Modular Medical, MODD, SEC Filing, 10-Q, Insulin Pump, Medical Device, Diabetes, FDA Clearance, Going Concern, Nasdaq Delisting, Financial Results, Q2 2025, MODD1, Pivot Pump, Capital Raise, R&D Expenses, SG&A Expenses